OBJECTIVE: This study compared the hospital and follow-up costs of patients who have undergone endovascular (EVAR) or open (OR) elective abdominal aortic aneurysm repair. METHODS: The records of 195 patients (EVAR, n = 55; OR, n = 140) who underwent elective aortic aneurysm repair between 1995 and 2004 were reviewed. Primary costing data were analyzed for 54 EVAR and 135 OR patients. Hospital costs were divided into preoperative, operative, and postoperative costs. Follow-up costs for EVAR patients were recorded, with a median follow-up time of 12 months. RESULTS: Mean preoperative costs were slightly higher in the EVAR group (AU $961/US $733 vs AU $869/US $663; not significant). Operative costs were significantly higher in the EVAR group (AU $16,124/US $12,297 vs AU $6077/US $4635; P < .001); this was entirely due to the increased cost of the endograft (AU $10,181/US $7,765 for EVAR vs AU $476/US $363 for OR). Postoperative costs were significantly reduced in the EVAR group (AU $4719/US $3599 vs AU $11,491/US $8,764; P < .001). Total hospital costs were significantly greater in the EVAR group (AU $21,804/US $16,631 vs AU $18,437/US $14,063; P < .001). The increase in total hospital costs was due to a significant difference in graft costs, which was not offset by reduced postoperative costs. The average follow-up cost per year after EVAR was AU $1316/US $999. At 1 year of follow-up, EVAR remained significantly more expensive than OR (AU $23,120/US $17,640 vs AU $18,510/US $14,122; P < .001); this cost discrepancy increased with a longer follow-up. CONCLUSIONS: EVAR results in significantly greater hospital costs compared with OR, despite reduced hospital and intensive care unit stays. The inclusion of follow-up costs further increases the cost disparity between EVAR and OR. Because EVAR requires lifelong surveillance and has a high rate of reintervention, follow-up costs must be included in any cost comparison of EVAR and OR. The economic cost, as well as the efficacy, of new technologies such as EVAR must be addressed before their widespread use is advocated.
OBJECTIVE: This study compared the hospital and follow-up costs of patients who have undergone endovascular (EVAR) or open (OR) elective abdominal aortic aneurysm repair. METHODS: The records of 195 patients (EVAR, n = 55; OR, n = 140) who underwent elective aortic aneurysm repair between 1995 and 2004 were reviewed. Primary costing data were analyzed for 54 EVAR and 135 OR patients. Hospital costs were divided into preoperative, operative, and postoperative costs. Follow-up costs for EVAR patients were recorded, with a median follow-up time of 12 months. RESULTS: Mean preoperative costs were slightly higher in the EVAR group (AU $961/US $733 vs AU $869/US $663; not significant). Operative costs were significantly higher in the EVAR group (AU $16,124/US $12,297 vs AU $6077/US $4635; P < .001); this was entirely due to the increased cost of the endograft (AU $10,181/US $7,765 for EVAR vs AU $476/US $363 for OR). Postoperative costs were significantly reduced in the EVAR group (AU $4719/US $3599 vs AU $11,491/US $8,764; P < .001). Total hospital costs were significantly greater in the EVAR group (AU $21,804/US $16,631 vs AU $18,437/US $14,063; P < .001). The increase in total hospital costs was due to a significant difference in graft costs, which was not offset by reduced postoperative costs. The average follow-up cost per year after EVAR was AU $1316/US $999. At 1 year of follow-up, EVAR remained significantly more expensive than OR (AU $23,120/US $17,640 vs AU $18,510/US $14,122; P < .001); this cost discrepancy increased with a longer follow-up. CONCLUSIONS: EVAR results in significantly greater hospital costs compared with OR, despite reduced hospital and intensive care unit stays. The inclusion of follow-up costs further increases the cost disparity between EVAR and OR. Because EVAR requires lifelong surveillance and has a high rate of reintervention, follow-up costs must be included in any cost comparison of EVAR and OR. The economic cost, as well as the efficacy, of new technologies such as EVAR must be addressed before their widespread use is advocated.
Authors: Courtney J Warner; Alexander J Horvath; Richard J Powell; Jesse A Columbo; Teri R Walsh; Philip P Goodney; Daniel B Walsh; David H Stone Journal: J Vasc Surg Date: 2015-04-30 Impact factor: 4.268
Authors: Sang Il Min; Seung-Kee Min; Sanghyun Ahn; Suh Min Kim; Daedo Park; Taejin Park; Jin Wook Chung; Jae Hyung Park; Jongwon Ha; Sang Joon Kim; In Mok Jung Journal: J Korean Med Sci Date: 2012-03-21 Impact factor: 2.153
Authors: Nathan K Itoga; Ning Tang; Diana Patterson; Rika Ohkuma; Raymond Lew; Matthew W Mell; Ronald L Dalman Journal: J Vasc Surg Date: 2018-06-28 Impact factor: 4.268
Authors: Sophie E Rowbotham; Doug Cavaye; Rene Jaeggi; Jason S Jenkins; Corey S Moran; Joseph V Moxon; Jenna L Pinchbeck; Frank Quigley; Christopher M Reid; Jonathan Golledge Journal: Trials Date: 2017-01-04 Impact factor: 2.279
Authors: Spencer W Trooboff; Zachary J Wanken; Barbara Gladders; Jesse A Columbo; Jon D Lurie; Philip P Goodney Journal: Circ Cardiovasc Qual Outcomes Date: 2020-05-07
Authors: Robert Hopkins; James Bowen; Kaitryn Campbell; Gord Blackhouse; Guy De Rose; Teresa Novick; Daria O'Reilly; Ron Goeree; Jean-Eric Tarride Journal: Vasc Health Risk Manag Date: 2008